The ARFIP1 Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which the ARFIP1 gene has been disrupted in the HT29 human colorectal adenocarcinoma cell line. This product comprises a heterogeneous pool of edited cells, enabling gene loss-of-function studies without the selective pressure of single-cell cloning. The polyclonal format is particularly advantageous for capturing population-level phenotypes relevant to colorectal cancer biology.
The HT29 cell line was originally established from a colon adenocarcinoma of a 44-year-old female patient and has been extensively characterized as an enterocyte-like model with differentiation potential. These cells form polarized monolayers and express epithelial markers, making them suitable for investigating intestinal epithelial biology, drug absorption, and tumorigenesis. The ARFIP1 knockout in this well-defined background provides a physiologically relevant system for functional analysis.
ARFIP1 functions as an effector for the ARF1 and ARF6 small GTPases, linking their activation by upstream regulators such as EGFR and PIP2 to the control of membrane trafficking and actin cytoskeleton dynamics. It interacts with clathrin and the AP-2 complex to mediate endocytosis, and signals downstream through cortactin, RAC1, CDC42, and the ARP2/3 complex to promote actin polymerization and focal adhesion turnover. These interactions position ARFIP1 as a critical coordinator of processes that govern cell migration and invasion in cancer.
In the HT29 context, disruption of ARFIP1 is expected to perturb normal coupling between endocytic trafficking and actin remodeling, potentially impairing migratory and invasive capabilities. The polyclonal knockout population captures a spectrum of mutations, enabling researchers to observe heterogeneous responses that mirror the genetic diversity of tumor cells. This model is especially valuable for dissecting the contribution of ARFIP1 to metastatic properties of colorectal adenocarcinoma cells.
This knockout product supports a range of experimental applications, including validation by Western blotting and RT-qPCR, Transwell migration and invasion assays, and immunofluorescence for actin and focal adhesion structures. Co-immunoprecipitation can be used to analyze interactions with cortactin or ARF proteins, while flow cytometry permits assessment of membrane protein trafficking. Additional approaches such as RNA-seq and drug response profiling further expand its utility in functional genomics and colorectal cancer metastasis research. For further details or technical assistance, please contact Ascent Research.
